US Health Authorities Review Safety of COVID Vaccines in Pregnant Women and Children
U.S. health officials are reviewing safety data on COVID-19 vaccines for pregnant women and children, amid ongoing discussions and studies on vaccine safety and potential risks. The evaluation aims to ensure public health safety and may influence future vaccination guidelines.
Federal health officials in the United States are currently evaluating safety data concerning COVID-19 vaccines administered to pregnant women and children. This review comes amid ongoing discussions about the vaccine's safety profile in these vulnerable populations. The U.S. Food and Drug Administration (FDA) is specifically analyzing reports of potential birth defects observed after vaccination during pregnancy and is preparing a presentation on pediatric deaths potentially linked to COVID vaccination.
The upcoming meeting with the CDC's vaccine advisory committee is scheduled for September 18 and 19, marking a critical step in assessing the current evidence. While investigating, experts emphasize that the main tool used—the Vaccine Adverse Event Reporting System (VAERS)—is primarily designed to identify potential safety signals rather than establish causality. Dr. Demetre Daskalakis, former director of the CDC's National Center for Immunization and Respiratory Diseases, clarified that VAERS generates hypotheses that require further study.
Large-scale studies, including monitoring over 23,000 pregnant women in one registry and more than 45,000 in another database, have so far indicated no increased risk of major birth defects, miscarriages, or other adverse pregnancy outcomes linked to COVID vaccines. Pfizer also reported that in clinical trials involving pregnant women, the rate of birth defects in vaccinated individuals was comparable to the general population.
FDA Commissioner Dr. Marty Makary has stated that the agency intends to release all safety data transparently to the medical community to address public concerns. Additionally, there is discussion about potentially updating vaccination guidelines for older adults, possibly recommending booster shots predominantly for those aged 75 and above, or for younger individuals with underlying health conditions. Currently, COVID vaccines are approved for adults 65 and older and for high-risk younger adults.
For further insights, the New England Journal of Medicine offers detailed information on COVID vaccine recommendations. Overall, health authorities continue to monitor and analyze the safety evidence to guide vaccination policies and reassure the public.
Source: https://medicalxpress.com/news/2025-09-covid-vaccine-safety-pregnancy-kids.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Strategy Targets Protein to Prevent Lung Tissue Changes in Asthma
A new study introduces a novel protein-targeting strategy that may prevent airway remodeling in asthma, offering hope for improved treatments to reduce tissue thickening and mucus overproduction.
Alzheimer's Protein Provides Insights for Cancer Treatment Strategies
Discover how the amyloid beta protein linked to Alzheimer's disease also plays a crucial role in enhancing immune response against cancer, opening new avenues for therapies targeting mitochondrial health and immune rejuvenation.
Inflammation and Nutrition Scores as Prognostic Indicators in Low-Risk Myelodysplastic Syndrome
New research identifies inflammation and nutritional scores as key prognostic indicators in low-risk myelodysplastic syndrome, potentially guiding future treatment strategies.
Uncovering the Hidden Diversity of Fibroblasts and Its Implications for Tissue Repair
New research uncovers the diverse subtypes of fibroblasts in human tissues, revealing their crucial roles in tissue repair and disease progression, paving the way for targeted therapies.